AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1342306 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1214
Study 1342306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1214
Study 6102677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular gentamicin plus systemic antimicrobial agents
Number of subjects: 52
Study 6102677 — intervention group
Group type: COMPARATOR
Intervention: Systemic ampicillin and gentamicin
Number of subjects: 52
Study 6102677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular gentamicin
Number of subjects: 52
Study 6102677 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 52
Study 29968519 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training group
Number of subjects: 52
Study 29968519 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 52
Study 31067131 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training at least three times per week
Number of subjects: 75
Study 31067131 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip isometric training five times weekly
Number of subjects: 75
Study 31067131 — intervention group
Group type: COMPARATOR
Intervention: Placebo-handgrip
Number of subjects: 75
Study 27564409 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 200 mg added to allopurinol
Number of subjects: 603
Study 27564409 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg added to allopurinol
Number of subjects: 603
Study 27564409 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol alone (Control)
Number of subjects: 603
Study 27564409 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 200 mg and 400 mg added to allopurinol
Number of subjects: 603
Study 27564409 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 200 mg
Number of subjects: 603
Study 25829346 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (bevacizumab plus dexamethasone delivery system)
Number of subjects: 30
Study 25829346 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab monotherapy
Number of subjects: 30
Study 23891461 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine therapy with escitalopram treatment for depressive symptoms
Number of subjects: 111
Study 23891461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 21521728 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 147020
Study 19297377 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 99
Study 19297377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 17074798 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg voriconazole twice daily (BID) (400-mg BID loading doses on the first day), n = 16
Number of subjects: 23
Study 17074798 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo, n = 7
Number of subjects: 23
Study 17074798 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg voriconazole twice daily (BID) with methadone
Number of subjects: 23
Study 16652380 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐week program of clinic‐based or self‐administered behavioral training
Number of subjects: 359
Study 14613070 — intervention group
Group type: EXPERIMENTAL
Intervention: End of Life Nursing Education Consortium (ELNEC) education package along with experiential learning (hospice, funeral home, anatomy laboratory, role play)
Number of subjects: 0
Study 10418181 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled, disposable insulin pen injector (Novolet)
Number of subjects: 19
Study 10418181 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringes
Number of subjects: 19
Study 7776075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine
Number of subjects: 100
Study 7776075 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 100
Study 1691403 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10-40 mg/day, up to 80 mg/day)
Number of subjects: 2187
Study 1691403 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (once daily)
Number of subjects: 2187
Study 1691403 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10-40 mg/day)
Number of subjects: 2187
Study 1691403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2187
Study 1691403 — intervention group
Group type: COMPARATOR
Intervention: Captopril (two or three times daily)
Number of subjects: 2187
Study 1691403 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (once daily)
Number of subjects: 2187
Study 1691403 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics (optional for nonresponders)
Number of subjects: 2187
Study 6271384 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy‐irradiation (CT‐RT)
Number of subjects: 71
Study 6271384 — intervention group
Group type: EXPERIMENTAL
Intervention: Three‐week course of concurrent CT‐RT
Number of subjects: 71
Study 6271384 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent therapy
Number of subjects: 71
Study 6271384 — intervention group
Group type: COMPARATOR
Intervention: Sequential CT‐RT
Number of subjects: 71
Study 31655841 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (K Laser Cube 3)
Number of subjects: 85
Study 31655841 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (placebo)
Number of subjects: 85
Study 28453740 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise at 65% of maximal aerobic capacity for 30 minutes
Number of subjects: 23
Study 26319423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vit B12 1000 microgram/day, B6 3 mg/day & folic acid 5 mg/day
Number of subjects: 12000
Study 26319423 — intervention group
Group type: COMPARATOR
Intervention: Control arm (existing interventions)
Number of subjects: 12000
Study 23305251 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy involving physician accountability, including distribution of patient lists compatible with discharge and physician length of stay profiles, followed by audits managed by ward physicians.
Number of subjects: 3498
Study 23305251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 3498
Study 23305251 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups.
Number of subjects: 3498
Study 21563042 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine topical patch 1.3%
Number of subjects: 418
Study 21563042 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 418
Study 18474882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention materials received by physicians
Number of subjects: 168
Study 18474882 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased antibiotic prescribing
Number of subjects: 168
Study 18474882 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge, attitudes, or behaviors favoring judicious antibiotic use
Number of subjects: 168
Study 18474882 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about antibiotic resistance
Number of subjects: 168
Study 18474882 — intervention group
Group type: EXPERIMENTAL
Intervention: Room to reduce prescribing
Number of subjects: 168
Study 16612452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pressure (Müller Resuscitator Group)
Number of subjects: 40
Study 16612452 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP Group)
Number of subjects: 40
Study 12709086 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 10844862 — intervention group
Group type: EXPERIMENTAL
Intervention: Agfa HDR film
Number of subjects: 54
Study 10844862 — intervention group
Group type: COMPARATOR
Intervention: Fuji UMMA film
Number of subjects: 54
Study 10844862 — intervention group
Group type: EXPERIMENTAL
Intervention: Agfa HDR film and Fuji UMMA film
Number of subjects: 54
Study 8804327 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered iron for 6 months
Number of subjects: 32
Study 8804327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1511045 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CLO)
Number of subjects: 9
Study 1511045 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (EN)
Number of subjects: 9
Study 1511045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF)
Number of subjects: 9
Study 1511045 — intervention group
Group type: COMPARATOR
Intervention: Washout period
Number of subjects: 9
Study 6229429 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 1.0 mg/kg
Number of subjects: 58
Study 6229429 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.5 mg/kg
Number of subjects: 58
Study 29767425 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing 15 times per bite
Number of subjects: 41
Study 29767425 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing 50 times per bite
Number of subjects: 41
Study 27099954 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice group
Number of subjects: 22
Study 27099954 — intervention group
Group type: EXPERIMENTAL
Intervention: Steamed buns group
Number of subjects: 22
Study 27099954 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 22
Study 24709495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4 μg/kg
Number of subjects: 90
Study 24709495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.8 μg/kg
Number of subjects: 90
Study 24709495 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 90
Study 22371640 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d) with Pegylated α-interferon-2a plus oral ribavirin 800 mg/d for 24 weeks
Number of subjects: 50
Study 22371640 — intervention group
Group type: COMPARATOR
Intervention: Control group received identical therapy without vitamin D
Number of subjects: 50
Study 22371640 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Number of subjects: 50
Study 22371640 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum vitamin D levels
Number of subjects: 50
Study 22371640 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI (< 30 or > 30)
Number of subjects: 50
Study 19756664 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of etanercept and methotrexate (MTX)
Number of subjects: 686
Study 19756664 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 686
Study 18441623 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair-washing 72 hours postoperatively (n = 48)
Number of subjects: 100
Study 18441623 — intervention group
Group type: COMPARATOR
Intervention: No hair washing until suture or clip removal (n = 52)
Number of subjects: 100
Study 15449975 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg/day for 6 weeks, then either maintained or increased to 8 mg/day based on BP response.
Number of subjects: 3010
Study 15449975 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day for 6 weeks (group II).
Number of subjects: 3010
Study 15449975 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril monotherapy.
Number of subjects: 3010
Study 15449975 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day for group II patients.
Number of subjects: 3010
Study 15449975 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril monotherapy in hypertensive diabetic patients.
Number of subjects: 3010
Study 15449975 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril treatment in very elderly patients (>75 years).
Number of subjects: 3010
Study 15449975 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril treatment.
Number of subjects: 3010
Study 11368989 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-placental insertion of a copper T380A intrauterine device (IUD)
Number of subjects: 302
Study 11368989 — intervention group
Group type: COMPARATOR
Intervention: No IUD insertion (control group)
Number of subjects: 302
Study 9045337 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m2 plus carboplatin (AUC 6)
Number of subjects: 16
Study 9045337 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2
Number of subjects: 16
Study 9045337 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2
Number of subjects: 16
Study 9045337 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin regimen
Number of subjects: 16
Study 8435379 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide 100 mg intravenous dose in patients with moderate renal insufficiency
Number of subjects: 24
Study 8435379 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide 200 mg intravenous dose in patients with severe renal insufficiency
Number of subjects: 24
Study 8435379 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (various doses)
Number of subjects: 24
Study 8435379 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 24
Study 3677786 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfluorex (450 mg/day)
Number of subjects: 22
Study 3677786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28501343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 278
Study 28501343 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet
Number of subjects: 278
Study 28501343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet with exercise
Number of subjects: 278
Study 28501343 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet with exercise
Number of subjects: 278
Study 28501343 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased sodium intake
Number of subjects: 278
Study 27557865 — intervention group
Group type: EXPERIMENTAL
Intervention: 67 % sodium bicarbonate-containing dentifrice
Number of subjects: 150
Study 27557865 — intervention group
Group type: COMPARATOR
Intervention: Commercially available NaF silica dentifrice without NaHCO3
Number of subjects: 150
Study 24497599 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexanide solution
Number of subjects: 60
Study 24497599 — intervention group
Group type: COMPARATOR
Intervention: Traditional care with saline serum and povidone-iodine
Number of subjects: 60
Study 23582589 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 1456
Study 23582589 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proANP
Number of subjects: 1456
Study 23582589 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 1456
Study 20081225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 89
Study 20081225 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 89
Study 20081225 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin vs Azathioprine
Number of subjects: 89
Study 20081225 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin and Azathioprine
Number of subjects: 89
Study 18374544 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (ARI) 10-30 mg/day
Number of subjects: 555
Study 18374544 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 555
Study 16651506 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic symptoms (positive and negative)
Number of subjects: 1410
Study 16651506 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurring substance abuse and interpersonal/social factors
Number of subjects: 1410
Study 16651506 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic and depressive symptoms, childhood conduct problems, and victimization
Number of subjects: 1410
Study 16651506 — intervention group
Group type: EXPERIMENTAL
Intervention: Any violence
Number of subjects: 1410
Study 12814905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron treatment (1, 4, and 16 micro g/kg twice daily)
Number of subjects: 0
Study 12814905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10508811 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg once daily for 2 weeks
Number of subjects: 26
Study 10508811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7484516 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide with orchiectomy
Number of subjects: 546
Study 7484516 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide with LHRH analogues
Number of subjects: 546
Study 7484516 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 546
Study 1851683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure treatment
Number of subjects: 9
Study 1851683 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control)
Number of subjects: 9
Study 7177292 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 22
Study 7177292 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 22
Study 7177292 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal subjects)
Number of subjects: 22
Study 29553345 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 40
Study 29553345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27286961 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-carboxymethylcellulose treatment (n=30)
Number of subjects: 60
Study 27286961 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 60
Study 24984823 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplements (8.1mmol of magnesium-pidolate, administered twice a day)
Number of subjects: 14
Study 24984823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 24984823 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplements
Number of subjects: 14
Study 22187144 — intervention group
Group type: EXPERIMENTAL
Intervention: Philos system (Philos, proximal humeral internal locking system, Synthes GmbH)
Number of subjects: 60
Study 22187144 — intervention group
Group type: COMPARATOR
Intervention: Königsee plate system (Königsee Implantate GmbH)
Number of subjects: 60
Study 20424828 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 58
Study 20424828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 20424828 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58
Study 18561516 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance on lifestyle modifications (single visit)
Number of subjects: 0
Study 18561516 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance on lifestyle modifications (multiple visits every two months)
Number of subjects: 0
Study 18561516 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 15864643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DX) 0.25 mg/kg at 12 h intervals for four doses
Number of subjects: 109
Study 15864643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DX) early prolonged (>96 h)
Number of subjects: 109
Study 15864643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DX) early short (<96 h)
Number of subjects: 109
Study 15864643 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 109
Study 11815760 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (1 mg/kg, 1 dose)
Number of subjects: 70
Study 11815760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 10087861 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexposure of the same problem in the same notation (number words and dot configurations)
Number of subjects: 0
Study 10087861 — intervention group
Group type: COMPARATOR
Intervention: Preexposure of the same problem in Arabic digit, number word, and dot notation
Number of subjects: 0
Study 10087861 — intervention group
Group type: EXPERIMENTAL
Intervention: Task performed on preexposure trials (addition or multiplication) matching the task on repetition trials (addition)
Number of subjects: 0
Study 10087861 — intervention group
Group type: EXPERIMENTAL
Intervention: Notation matching across repetitions (number words and dot configurations)
Number of subjects: 0
Study 10087861 — intervention group
Group type: COMPARATOR
Intervention: Notation matching across repetitions (Arabic digits)
Number of subjects: 0
Study 7752010 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 99
Study 2311727 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 33
Study 2311727 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 33
Study 6161451 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcoseryl gel
Number of subjects: 60
Study 6161451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence microscopy
Number of subjects: 60
Study 6353619 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray (200 micrograms, twice daily for 4 weeks)
Number of subjects: 20
Study 6353619 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20
Study 6353619 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray
Number of subjects: 20
Study 6353619 — intervention group
Group type: COMPARATOR
Intervention: Flunisolide nasal spray and Placebo
Number of subjects: 20
Study 30246883 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (weight reduction diet + bolus weekly dose of 50,000 IU vitamin D)
Number of subjects: 44
Study 30246883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (weight reduction diet + edible paraffin weekly)
Number of subjects: 44
Study 28823697 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelfoam patch‐treated group
Number of subjects: 114
Study 28823697 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing group
Number of subjects: 114